Top managers of Promomed Group spoke about import substitution, in-novative products and the development of biotechnological production

Promomed 27 December 2023

Representatives of Promomed Group took part in the business breakfast "Im-port substitution of medicines in the healthcare sector: results of 2023 and develop-ment prospects in 2024", organized by the Moscow City Investment Agency. On the part of Promomed, the event was attended by Petr Bely, Chairman of the Board of Directors of Promomed Group, and Alexander Efremov, CEO of Promomed Group.

Speakers at the event were Vladislav Ovchinsky, Minister of the Government of Moscow, Director of the Department of Investment and Industrial Policy of the City of Moscow, Dmitry Galkin, Director of the Department of Pharmaceutical and Medical Industry Development of the Ministry of Industry and Trade of the Russian Federation, Yulia Antipova, Deputy Head of the Department of Health of the City of Moscow, and representatives of government authorities and large pharmaceutical companies.

Petr Bely drew special attention to the importance of supporting domestic pharmaceutical companies at the stage of clinical trials. He also noted that the Pro-momed Group’s strategy aimed at the production of innovative medicines and the introduction of high technologies is in line with the task set by the Russian Govern-ment to deepen the sovereignty of the pharmaceutical industry and strengthen the national pharmaceutical security.

Alexander Efremov, in his report "Import substitution and innovative products as the main goal of the development of Promomed's biotechnology production in Moscow," recalled that the Department of Investment and Industrial Policy of the City of Moscow and Promomed Group signed a cooperation Agreement at SPIEF 2023. This agreement includes provisions for the creation of a modern research la-boratory with a pilot production site for the development of new drugs, including original ones, at the Technopolis sites Alabushevo and Pechatniki.

Alexander also talked about factors allowing the Group to reach a new tech-nological level: "Promomed lays high technologies in the basis of its activities. The group includes Biokhimik plant in Saransk, which launched the country's largest production of active pharmaceutical substances in 2023. Russian President Vladimir Vladimirovich Putin took part in the opening ceremony of this production. This plant is second to none in Russia in terms of capacity, we are ahead, and we are ready to synthesize substances never produced before.

Our work is also based on an innovative approach. We are able to combine technology, scientific research and the specifics of production. This work results in the production of medicines that treat more effectively and safely and which are of-ten the first of a kind. For example, our anti-COVID drugs fight the virus at the most basic level, blocking the viral replication. These are Areplivir, Esperavir, Skyvira. Tech-nologically, there is no drug similar to Skyvira until now.

Biotechnology is another key area for Promomed Group. We are developing biotechnological products, which we plan to bring to the platform of the Moscow pharmaceutical cluster.

Import substitution is an important issue for us. In 2023, in just seven months, Promomed developed, put into production and released two drugs, Kvinsenta and Enligria, for the treatment of diabetes mellitus (including in obese patients) to re-place drug products of a foreign manufacturer that stopped supplies to Russia. This development has given rise to new research that we are conducting in Moscow in order to provide patients in Russia and abroad with vital medicines."